CD33 and acute myeloid leukemia: The coupling of the humanized monoclonal antibody (mAb) Gemtuzumab ozogamicin, which targets the CD33 antigen expressed in the hematopoietic system, to CAL enables precise targeting of transformed cells with minimal general cytotoxicity in acute myeloid leukemia (AML) [66].